Umer Raffat
Stock Analyst at Evercore ISI Group
(1.43)
# 3,442
Out of 5,182 analysts
19
Total ratings
56.25%
Success rate
-3.92%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $69.67 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $17.04 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $0.62 | - | 1 | Feb 28, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $33.31 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $39.47 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Outperform | n/a | $30.64 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $11.70 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $27.51 | - | 1 | Mar 7, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $23.90 | - | 1 | Nov 2, 2022 | |
| OGN Organon & Co. | Initiates: Outperform | n/a | $11.26 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $44.84 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $960 | $13.81 | +6,851.48% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $344.55 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $5.15 | +832.04% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $196.52 | - | 1 | Feb 23, 2017 |
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $69.67
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $17.04
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.62
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $33.31
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $39.47
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $30.64
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $11.70
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $27.51
Upside: -
Legend Biotech
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $23.90
Upside: -
Organon & Co.
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.26
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $44.84
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $960
Current: $13.81
Upside: +6,851.48%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $344.55
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $5.15
Upside: +832.04%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $196.52
Upside: -